Clin2Atlas
AtlasCancersNeoplasms

Cervical cancer

4Curable or preventable in mostAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251996 — Topotecan approved (FDA)2004 — Bevacizumab approved (FDA)2021 — Tisotumab vedotin approved (FDA)
1996: Drug approval — Topotecan approved (FDA). 2004: Drug approval — Bevacizumab approved (FDA). 2021: Drug approval — Tisotumab vedotin approved (FDA)

What's being tested now

2000: 1 trials started2002: 1 trials started2006: 1 trials started2008: 1 trials started2009: 1 trials started2011: 2 trials started2013: 1 trials started2015: 2 trials started2016: 5 trials started2017: 6 trials started2018: 5 trials started2019: 10 trials started2020: 26 trials started2021: 33 trials started2022: 43 trials started2023: 87 trials started2024: 128 trials started2025: 135 trials started2026: 107 trials started2000201020202026135

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 566 active Cervical Cancer trials on Clin2 →

Related

Lip and oral cavity cancerNasopharynx cancerOther pharynx cancerEsophageal cancerStomach cancerColon and rectum cancerGallbladder and biliary tract cancerPancreatic cancerLarynx cancerTracheal, bronchus, and lung cancerMalignant skin melanomaSoft tissue and other extraosseous sarcomas

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.